# Fudan University: Phase 2 study in HER2-positive Breast Cancer, Early Breast Cancer (EBC) (358 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Fudan University |
| Sponsor type | Academic and hospital |
| Study | SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response |
| NCT ID | NCT07856303 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | HER2-positive Breast Cancer; Early Breast Cancer (EBC) |
| Intervention types | drug |
| Target enrollment | 358 |
| Site countries | China |
| Posted | 2026-10-02 |
| Planned start | 2026-10-01 |
| Event | Newly registered study |
| Event date | 2026-10-02 |

## Why this score
- Phase 2: multi-site, larger budget.
- 358 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07856303). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.